검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | immune evaluation (immune evaluation) Istituto Clinico Humanitas·Oligorecurrent and Oligoprogressiv… ORR 37.5% |
|---|---|
Overview Program | immune evaluation |
Overview Company | Istituto Clinico Humanitas |
Overview Modality | CGT |
Overview Target | Oligorecurrent and Oligoprogressive Pros |
Overview Indication | Oligorecurrent and Oligoprogressive Prostate Cancer Patients |
Overview Phase | PRECLINICAL |
Overview Status | RECRUITING |
MoA Mechanism | of B-cell depleting agents, the clinical utility and adverse effects of these therapies, and the relevance of systematic and serial laboratory immune monitoring in identifying patients at risk for developing immunologic |
MoA Biomarker | biomarkers |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | The Ave-Rec Trial: Phase II Trial of PDL1/PD1 Blockade with Avelumab after Chemoradiotherapy for Locally Advanced Resectable T3B-4/N1-2 Rectal Cancer.. Long-course chemoradiotherapy (LCCRT) for locally advanced rectal cancer (LARC) achieves a pathologic complete response (pCR) in approximately 10% to 30% of cases. Radiotherapy exerts both immunostimulatory and immunosuppressive effects. Inhibition… |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 37.5% |
Clinical ORR | 37.5% |
Clinical Result source | ClinicalTrials.gov NCT05228470 |
Clinical Data Tier / Score | A · 37 |
Clinical Program phase | PRECLINICAL |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | immune evaluation (immune evaluation) Istituto Clinico Humanitas·Oligorecurrent and Oligoprogressiv… ORR 37.5% |
|---|---|
Overview Program | immune evaluation |
Overview Company | Istituto Clinico Humanitas |
Overview Modality | CGT |
Overview Target | Oligorecurrent and Oligoprogressive Pros |
Overview Indication | Oligorecurrent and Oligoprogressive Prostate Cancer Patients |
Overview Phase | PRECLINICAL |
Overview Status | RECRUITING |
MoA Mechanism | of B-cell depleting agents, the clinical utility and adverse effects of these therapies, and the relevance of systematic and serial laboratory immune monitoring in identifying patients at risk for developing immunologic |
MoA Biomarker | biomarkers |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | The Ave-Rec Trial: Phase II Trial of PDL1/PD1 Blockade with Avelumab after Chemoradiotherapy for Locally Advanced Resectable T3B-4/N1-2 Rectal Cancer.. Long-course chemoradiotherapy (LCCRT) for locally advanced rectal cancer (LARC) achieves a pathologic complete response (pCR) in approximately 10% to 30% of cases. Radiotherapy exerts both immunostimulatory and immunosuppressive effects. Inhibition… |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 37.5% |
Clinical ORR | 37.5% |
Clinical Result source | ClinicalTrials.gov NCT05228470 |
Clinical Data Tier / Score | A · 37 |
Clinical Program phase | PRECLINICAL |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
추천 비교
추천 비교